Tricyclic antidepressants treatment can increase glucose levels and reduce insulin levels in animals and humans, thus increasing metabolic risks in nondiabetic patients with depression or deteriorating glucose homeostasis and aggravating glucose intolerance in T2DM patients with depression [28,56,57]. The gene discussed is INS; the disease is depressive disorder.